Evaluation of the Safety and Efficacy of the D.D.C Dual-control Technology Spectacle Lenses in Delaying the Progression of Myopia: a Randomized Controlled Trial
A legfontosabb adatok
- Ki végzi
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 316 fő, tervezett
- Kezdés
- 2026. márc. 23.
- Várható befejezés
- 2027. dec. 20.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- D.D.C dual-control technology spcetacle lenses
- Aspheric single-vision lenses
- A regiszteradat frissítve
- 2026. július 28.
Ki vehet részt
- Életkor
- 8 év – 12 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Age between 6 and 14 years
- Cycloplegic spherical equivalent refraction between -1.50 D and -5.00 D with astigmatism ≥ -1.50 D in both eyes
- Absolute interocular difference in spherical equivalent refraction ≤ 1.50 D
- Binocular best-corrected visual acuity ≥ 1.0
- Intraocular pressure between 10 and 21 mmHg in both eyes
- Volunteer to participate in this clinical trial with signature of the informed consent form
Ki nem vehet részt
- Participation in a drug clinical trial within 3 months or a device clinical trial within 1 month prior to enrollment
- History of eye injury or intraocular surgery or ocular trauma
- Presence of ocular diseases such as cataract, glaucoma, fundus pathology, ocular trauma, manifest strabismus, or any other condition affecting visual function
- Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
- Participation in any myopia control clinical trial within the past 3 months and a history of myopia control interventions (e.g., orthokeratology, atropine)
- Clinically abnormal slit-lamp findings
- Abnormal fundus examination
- Only one eye meeting the inclusion criteria
- Inability to attend regular ophthalmic examinations
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The burden of myopia among Chinese children and adolescents is severe and trending toward younger ages, making control of myopia progression a public health priority. Current mainstream strategies include optical interventions, pharmacologic therapy, and environmental measures. Among these strategies, spectacle designs based on optical defocus-such as defocus-incorporated multiple-segment (DIMS) lenses-have demonstrated efficacy; however, the effect of such designs may attenuate over time because of "defocus adaptation." To address this limitation, D.D.C dual-control spectacles employ a densely staggered microlens layout, a gradient-defocus architecture, and an added peripheral "fogging zone" to disrupt the spatial distribution of defocus cues and reduce contrast, thereby delaying adaptation and enhancing myopia-control efficacy.
A teljes eredeti leírásKevesebb
The present study therefore proposes a 24-month prospective randomized controlled trial in Guangzhou, enrolling eligible myopic adolescents. The trial will first compare 12-month outcomes between D.D.C-A lenses and single-vision lenses, followed by a crossover and alternating-wear phase, to systematically evaluate the safety and efficacy of the D.D.C technology in slowing myopia progression.
A vizsgálat 2 csoportja
- InterventionA vizsgált kezelés
D.D.C dual-control technology spectacle lenses
Kezelés: D.D.C dual-control technology spcetacle lenses
- ControlA vizsgált kezelés
Aspheric single-vision spectacle lenes
Kezelés: Aspheric single-vision lenses
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2026. július 28.